u/Exact_Journalist_426

Author argues Arcturus Therapeutics offers binary upside from two near-term catalysts: ARCT-810 OTC deficiency Phase 2 data expected later in September 2026 (with regulatory path disclosed for adults and pediatrics) and an ARCT-032 cystic fibrosis Phase 3 go/no-go decision in Q4 2026 that would unlock up to $40 million non-dilutive funding from Thermo Fisher. The bull case rests on a differentiated inhaled mRNA platform (biodegradable LNP, improved RNA purification, custom nebulizer) that management claims solved the safety/tolerability barrier that sank prior inhaled RNA programs, plus KOSTAIVE vaccine revenue funding the therapeutics pipeline without dilution. Author frames the next 3-6 months as potentially decisive for the company's trajectory. Main stated risk: clinical-stage biotech binary outcomes, where unfavorable data or decisions would hurt the stock.